MSCTC Current Studies

Currently Recruiting for Phase II Heart Attack Clinical Trial

The Midwest Stem Cell Therapy Center (MSCTC), with the University of Kansas Medical Center and Hospital, is currently recruiting heart attack patients for the Phase II "ALLSTAR" clinical trial, sponsored by Capricor, Inc. (Capricor).

In the "ALLSTAR" (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration) trial, the MSCTC and Capricor are investigating whether heart-derived adult stem cells directly infused into the area affected by a heart attack can repair heart muscle that is dead or has been damaged as a result of that heart attack. The infusion contains Capricor's proprietary off-the-shelf stem cell product, CAP-1002, that is derived from donor heart tissue.  

Patients who qualify to participate must have had a heart attack within the prior 12 month period. The effectiveness of the investigational product will be measured by a pre-treatment and post-treatment MRI that detects and measures scar size.

For patients who would like to be considered for this study, please speak with your cardiologist or call the study coordinator at (913) 588-9722. To view the most up-to-date information about the study, including inclusion and exclusion criteria, visit ClinicalTrials.gov (NCT01458405).

Are you a physician? Visit https://www.referanallstar.com/ to learn more! 

Principal Investigator, Buddhadeb Dawn, MD


No longer enrolling, in long-term follow up

A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction (Pre-SERVE AMI), sponsored by Amorcyte.

Principal Investigator, Buddhadeb Dawn, MD

The primary objective of the study is to determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion using the resting total severity score (RTSS), measured by gated SPECT MPI at baseline and six months, in subjects with STEMI.

Single-center randomized double-blind placebo-controlled phase 2 proof of concept study to assess the efficacy and safety of ASCT01 in Patients with Critical Limb Ischemia, sponsored by Lifecells LLC.

Principal Investigator, Buddhadeb Dawn, MD

The primary objective of this trial is to compare the effects of treatment with ASCT01 with placebo in patients with critical limb ischemia who have exhausted all options for revascularization.


Last modified: Apr 06, 2016
Not what you’re looking for?

Visit ClinicalTrials.gov to see what other adult stem cell trials are being conducted. ClinicalTrials.gov provides patients, their family members, and the public with easy and free access to information on clinical studies for a wide range of diseases and conditions. 

For tips on how to search on ClinicalTrials.gov and a list of "ready-made" clinical trial searches, click here

I want to...
ID=x15778